This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): adalimumab, ABT-D2E7, Trudexa
Description: Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Humira binds specifically to TNF-alpha and blocks interaction with the p55 and p75 cell surface TNF receptors. Humira also lyses surface TNF expressing cells in the presence of complement.
Humira was the first fully-human therapeutic monoclonal antibody to be approved by the FDA. Available data strongly suggest that Humira benefits patients with refractory rheumatoid arthritis.
Humira directly competes with Enbrel and Remicade. All three of these drugs function by blocking TNFalpha.
Deal Structure: Cambridge Antibody Technologies (CAT) developed Humira and licensed it to BASF, whose drug division was purchased by Abbott in 2001. CAT, in conjunction with Abbott, has isolated and optimised human monoclonal antibodies against the first two nominated targets, TNF alpha and Interleukin-12 (Humira and ABT-874 respectively). The development of ABT-874 involved the partnership of Abbott and the Genetics Institute (a research unit of Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products) together with CAT.
In June 1999, Eisai and Knoll AG, representing BASF Pharma, concluded a license agreement for the joint development of D2E7 (Humira) for the treatment of rheumatoid arthritis in Japan. Under the terms of the agreement, Eisai and Knoll Japan, a subsidiary of Knoll AG, will clinically co-develop the compound in Japan. Eisai Co. Ltd. will also be granted a license to sell the pharmaceutical product in the territories of Japan, Taiwan and Korea, pending the...See full deal structure in Biomedtracker
Partners: Royalty Pharma AG Eisai Co., Ltd.
Additional information available to subscribers only: